Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:IMRN

Immuron (IMRN) Stock Price, News & Analysis

Immuron logo

About Immuron Stock (NASDAQ:IMRN)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$1.85
$2.13
50-Day Range
$4.80
$5.61
52-Week Range
$1.68
$3.09
Volume
12,391 shs
Average Volume
9,568 shs
Market Capitalization
$10.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Buy

Company Overview

Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.

Remove Ads

Immuron Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
38th Percentile Overall Score

IMRN MarketRank™: 

Immuron scored higher than 38% of companies evaluated by MarketBeat, and ranked 638th out of 901 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Immuron has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Immuron has received no research coverage in the past 90 days.

  • Read more about Immuron's stock forecast and price target.
  • Earnings Growth

    Earnings for Immuron are expected to decrease in the coming year, from ($0.02) to ($0.03) per share.

  • Price to Book Value per Share Ratio

    Immuron has a P/B Ratio of 1.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.21% of the float of Immuron has been sold short.
  • Short Interest Ratio / Days to Cover

    Immuron has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Immuron has recently decreased by 35.43%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Immuron does not currently pay a dividend.

  • Dividend Growth

    Immuron does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.21% of the float of Immuron has been sold short.
  • Short Interest Ratio / Days to Cover

    Immuron has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Immuron has recently decreased by 35.43%, indicating that investor sentiment is improving significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, Immuron insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 7.01% of the stock of Immuron is held by insiders.

    • Percentage Held by Institutions

      Only 0.12% of the stock of Immuron is held by institutions.

    • Read more about Immuron's insider trading history.
    Receive IMRN Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Immuron and its competitors with MarketBeat's FREE daily newsletter.

    IMRN Stock News Headlines

    Trump Treasure April 19
    Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly that, just 12 months later…
    Immuron Limited Sponsored ADR
    Immuron reports strong sales growth of Travelan
    Immuron Travelan® continued strong sales growth
    See More Headlines

    IMRN Stock Analysis - Frequently Asked Questions

    Immuron (IMRN) raised $6 million in an IPO on Friday, June 9th 2017. The company issued 600,000 shares at a price of $9.99 per share. Joseph Gunnar and Rodman & Renshaw (a unit of H.C. Wainwright & Co.) served as the underwriters for the IPO and WallachBeth Capital was co-manager.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Immuron investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), AbbVie (ABBV), VBI Vaccines (VBIV), CRISPR Therapeutics (CRSP) and Dynavax Technologies (DVAX).

    Company Calendar

    Today
    4/07/2025
    Fiscal Year End
    6/30/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    Pharmaceutical preparations
    Sub-Industry
    N/A
    Current Symbol
    NASDAQ:IMRN
    Employees
    N/A
    Year Founded
    N/A

    Price Target and Rating

    Average Stock Price Target
    $5.00
    High Stock Price Target
    $5.00
    Low Stock Price Target
    $5.00
    Potential Upside/Downside
    +184.9%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.00
    Research Coverage
    1 Analysts

    Profitability

    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Pretax Margin
    N/A

    Debt

    Sales & Book Value

    Annual Sales
    $3.21 million
    Price / Cash Flow
    N/A
    Book Value
    $1.46 per share
    Price / Book
    1.20

    Miscellaneous

    Free Float
    5,429,000
    Market Cap
    $10.25 million
    Optionable
    Not Optionable
    Beta
    1.38
    Elon Musk's Next Move Cover

    Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.

    Get This Free Report

    This page (NASDAQ:IMRN) was last updated on 4/7/2025 by MarketBeat.com Staff
    From Our Partners